$OACB News
Last published 1y ago
- 1y agoBWGDMOEHIEMD+13Certain Closed-end Funds Advised by Franklin Templeton Fund Adviser, LLC Announce Appointment of New Chair and DirectorsBusiness WireBrandywineGLOBAL – Global Income Opportunities Fund Inc. ("BWG") Clarion Partners Real Estate Income Fund Inc. ("CPREIF") ClearBridge Energy Midstream Opportunity Fund Inc. ("EMO") LMP Capital and Income Fund Inc.
- 4y agoOACBAlvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business CombinationBusiness WireBusiness Combination anticipated to close on or about June 15, 2022 Ordinary shares of Alvotech expected to trade under the new ticker symbol "ALVO" from June 16, 2022 on The Nasdaq Stock Market in New York and from June 23, 2022 on the Nasdaq
- 4y agoOACBOaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with AlvotechBusiness WireBusiness Combination remains subject to satisfaction of customary closing conditions, including shareholder approval Oaktree Acquisition Corp. II (NYSE:OACB) ("OACB" or the "Company") announced today that, assuming satisfaction of the conditions to t
- 4y agoOACBOACB.UAlvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®Business WireThe confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara® (ustekinumab) met its primary endpoint AVT04 (ustekinumab) is part of a broader pipeline of Alvotech's biosimilars and biosimilar candidates, which i
- 4y agoOACBOACB.UAlvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®Business Wire- Results from pharmacokinetic (PK) similarity study demonstrate bioequivalence of AVT04 (ustekinumab) to the reference product Stelara® Alvotech Holdings S.A. ("Alvotech"), a global biotech company focused solely on the development and manufacture
- 4y agoOACBAlvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business CombinationBusiness WireAlvotech Holdings S.A. ("Alvotech S.A."), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (NYSE:OACB), a special purpose acquisition co
- 4y agoOACBOACB.UAlvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock ExchangeBusiness WireAlvotech and Oaktree Acquisition Corp. II establish financing facilities to enhance the company's capital position and to replace any redeemed capital as part of their proposed merger Parties agree to reduce the minimum cash condition outlined in the
- 4y agoOACBOACB.UAlvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVieBusiness WireUpon launch, HUKYNDRA® will be one of two citrate-free, high-concentration adalimumab biosimilars on the European market All intellectual-property disputes related to market entry of Alvotech's AVT02 (adalimumab) in the U.S. and Europe are n
- 4y agoABBVOACBAlvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech's Proposed High-Concentration Biosimilar (AVT02) for Humira®Business WireAlvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023 All ongoing U.S. disputes between AbbVie and Alvotech have been resolved, including the ITC action brought forth in December 2021 Alv
- 4y agoOACBFDA Accepts Alvotech's BLA Supporting Interchangeability for ATV02, a High Concentration, Citrate-Free Biosimilar Candidate for Humira®Business WireAlvotech is the only known company to have both developed a high-concentration biosimilar to Humira and conducted a switching study to support interchangeability Alvotech Holdings S.A. ("Alvotech"), a global biopharmaceutical company focused solely o
- 4y agoOACBAlvotech and Fuji Pharma Expand Partnership for Additional Biosimilar Candidate in JapanBusiness WireFuji and Alvotech partnership now covers six proposed biosimilar products Alvotech Holdings S.A. ("Alvotech"), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Ja
- 4y agoOACBAlvotech Enters Exclusive Global Licensing Agreement with BiosanaPharma for Co-Development of a Proposed Biosimilar (AVT23) to Xolair® (Omalizumab)Business WireAlvotech Holdings S.A. ("Alvotech"), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, has entered into an exclusive global licensing agreement with BiosanaPharma to co-d
- 4y agoOACBAlvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 MillionBusiness WireAlvotech Holdings S.A. ("Alvotech"), a leading global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II ("Oaktree II") (NYSE:OACB), a publicly tra
- 4y agoOACBJAMP and Alvotech Announce Canadian Approval of SIMLANDI™, a High-Concentration Biosimilar to Humira®, Providing Access to Previously Unavailable Versions in CanadaBusiness WireHealth Canada rules that 40 mg/0.4 mL and 80 mg/0.8 mL presentations of SIMLANDI™ are not subject to the statutory stay, clearing the way for the launch in the Canadian market High-concentration formulations, previously unavailable in Canada, refle
- 4y agoOACBAVT02, Alvotech's Biosimilar to High Concentration Formulation of Adalimumab (Humira®) Approved for Use in European UnionBusiness WireAlvotech Holdings S.A. ("Alvotech"), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, received approval for AVT02 (100 mg/mL), the company's high concentration biosimila
- 4y agoGDPMPHXOACBVGIIMoore Kuehn Encourages OACB, VGII, GDP, and MPHX Investors to Contact Law FirmPR NewswireNEW YORK, Dec. 14, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to sha
- 4y agoOACBOACB.UAlvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical CompanyBusiness WireAlvotech is a leading pure play biosimilar platform focused on the development and manufacture of high-quality biosimilar medicines for global markets. Biosimilars are therapeutic equivalents to biologics, a rapidly growing category of highly efficaci
- 6y agoOACBOaktree Acquisition Corp. II Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing November 9, 2020Business WireLOS ANGELES--(BUSINESS WIRE)--Oaktree Acquisition Corp. II (NYSE: OACB.U) (the “Company”) announced that, commencing November 9, 2020, holders of the units sold in the Company’s initial public offering of 25,000,000 units, completed on September 21, 2020, may elect to separately trade the Class A ordinary shares and warrants included in the units. Any units not separated will continue to trade on ...
- 6y agoOACBOaktree Acquisition Corp. II Announces Closing of Initial Public Offering and Partial Exercise of Overallotment OptionBusiness WireLOS ANGELES--(BUSINESS WIRE)--Oaktree Acquisition Corp. II, (the “Company”), a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced the closing of its initial public offering of 25,000,000 units, which includes the exercise in part by the u ...
- 6y agoOACBOaktree Acquisition Corp. II Announces Pricing of $225 Million Initial Public OfferingBusiness WireLOS ANGELES--(BUSINESS WIRE)--Oaktree Acquisition Corp. II, (the “Company”), a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced the pricing of its initial public offering of 22,500,000 units at a price of $10.00 per unit. The units will ...